Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials

Yang Yingying; Pan Hui; Wang Bo; Chen Shi; Zhu Huijuan

Your Location：

Home >

Browse articles >

Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials

Chinese Medical Sciences Journal Vol. 32, Issue 1, Pages: 22-27(2017)

Orginal Article | Updated：2024-04-10

- Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials
- Affiliations：
  
  1. 1Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
  2. 2Health Science Popularization Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
- Author bio：
  
  *Corresponding author Tel: 86-10-69155845, E-mail: pan20111111@163.com
- Funds：
- DOI：
  CLC：
- Published Online：11 April 2017，
  
  Published：2017-04
- Accepted：
Scan QR Code
Yang Yingying, Pan Hui, Wang Bo, et al. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials[J]. Chinese medical sciences journal, 2017, 32(1): 22-27.
DOI：

Yang Yingying, Pan Hui, Wang Bo, et al. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials[J]. Chinese medical sciences journal, 2017, 32(1): 22-27. DOI：

摘要

Abstract

Objective

To assess the efficiency and safety of a novel sodium-glucose co-transporter 2 (SGLT2) inhibitor—SGLT2 inhibitors

in combination with insulin for type 1 diabetes mellitus (T1DM).

Methods

We searched Medline

Embase

and the Cochrane Collaboration Library to identify the eligible studies published between January 2010 and July 2016 without restriction of language. The Food and Drug Administration (FDA) data and ClinicalTrials (http://www.clinicaltrials.gov) were also searched. The included studies met the following criteria: randomized controlled trials; T1DM patients aged between 18 and 65 years old; patients were treated with insulin plus SGLT2 inhibitors for more than 2 weeks; patients’ glycosylated hemoglobin (HbA1c) levels were between 7% and 12%. The SGLT2 inhibitors group was treated with SGLT2 inhibitors plus insulin

and the placebo group received placebo plus insulin treatment. The outcomes should include one of the following items: fasting blood glucose

HbA1c

glycosuria

or adverse effects. Data were analyzed by two physicians independently. The risk of bias was evaluated by using the Cochrane Collaboration’s Risk of Bias tool and heterogeneity among studies was assessed using Chi-square test. Random effect model was used to analyze the treatment effects with Revman 5.3.

Results

Three trials including 178 patients were enrolled. As compared to the placebo group

SGLT2 inhibitor absolutely decreased fasting blood glucose [mean differences (

) -2.47 mmol/L

95% confidence interval (

) -3.65 to -1.28

0.001] and insulin dosage (standardized MD -0.75 U

95%

-1.17 to -0.33

0.001). SGLT2 inhibitors could also increase the excretion of urine glucose (

131.09 g/24 h

95%

91.79 to 170.39

0.001). There were no significant differences in the incidences of hyperglycemia [odds ratio (

) 1.82

95%

0.63 to 5.29

=0.27]

urinary tract infection (

0.95

95%

0.19 to 4.85

=0.95)

genital tract infection (

0.27

95%

0.01 to 7.19

=0.43)

and diabetic ketoacidosis (

6.03

95%

0.27 to 135.99

=0.26) between the two groups.

Conclusion

SGLT2 inhibitors combined with insulin might be an efficient and safe treatment modality for T1DM patients.

关键词

Keywords

references

Vehik K and Dabelea D . The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011 ; 27 : 3 - 13 .

Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015 ; 66 : 255 - 70 .

Saulsberry WJ , Coleman CI , Mearns ES , et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract 2015 ; 69 : 1221 - 35 .

Diabetes mellitus . Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985 ; 727 : 1 - 113 .

Henry RR , Rosenstock J , Edelman S , et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015 ; 38 : 412 - 9 .

Pieber TR , Famulla S , Eilbracht J , et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015 ; 17 : 928 - 35 .

Sands AT , Zambrowicz BP , Rosenstock J , et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015 ; 38 : 1181 - 8 .

Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol 2015 ; 2015 : 676191 .

Vouyiouklis M. Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med 2013 ; 80 : 683 - 7 .

Kirkham JJ , Dwan KM , Altman DG , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010 ; 340 : c365 .

Tanaka M. Relationship between fasting and 2-hour postprandial plasma glucose levels and vascular complications in patients with type 2 diabetes mellitus. J Int Med Res 2012 ; 40 : 1295 - 303 .

Tahrani AA , Barnett AH , Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013 ; 1 : 140 - 51 .

Palmer SC , Mavridis D , Nicolucci A , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016 ; 316 : 313 - 24 .

Comee M , Peters A. The changing therapeutic armamentarium for patients with type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2016 ; 23 : 106 - 10 .

Scheen AJ. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 2015 ; 14 : 1879 - 904 .

Hinnen D. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2015 ; 6 : 92 - 102 .

Handelsman Y , Henry RR , Bloomgarden ZT , et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016 ; 22 : 753 - 62 .

Views

4513

Downloads

CSCD

Alert me when the article has been cited

Submit

Publicity Resources

Association between GSTT1 Homozygous Deletion and Risk of Pancreatic Cancer: A Meta Analysis

利妥昔单抗在特发性膜性肾病中的治疗

Related Author

Cui Junpeng

Lin Meiyi

Liu Zhenghao

Liu Baolin

Zou Peimei

Li Hang

Cai Jianfang

Chen Zhenjie

Related Institution

Sixth Department of General Surgery, Shengjing Hospital of China Medical University

Department of Rheumatology, First Affiliated Hospital of China Medical University

China Medical University

Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

⁰